July 31, 2018 02:51 PM EDT

The Google of CRISPR tech? Tech legends Tim Cook and Jeff Huber back Mammoth Biosciences

Brittany Meiling

A startup led by a group of Bay Area grad students says it’s building a platform that harnesses the “search engine” function of CRISPR, winning $23 million in backing from a slew of high profile investors Tuesday.

The company, called Mammoth Biosciences, was co-founded by CRISPR legend Jennifer Doudna — one of the most famous scientific pioneers behind CRISPR/Cas9 gene editing tech. The other founders include the 29-year-old CEO Trevor Martin, a Stanford PhD, and CTO Ashley Tehranchi, also out of Stanford. The duo launched the company with the help of two students in Doudna’s lab: Janice Chen and Lucas Harrington, who will lead scientific research. Doudna heads up the scientific advisory board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

The Google of CRISPR tech? Tech legends Tim Cook and Jeff Huber back Mammoth Biosciences

Brittany Meiling

Unlock this article instantly by becoming a free subscriber.

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing

The Google of CRISPR tech? Tech leg­ends Tim Cook and Jeff Hu­ber back Mam­moth Bio­sciences

Brittany Meiling

Unlock this article instantly by becoming a free subscriber.

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

The Google of CRISPR tech? Tech legends Tim Cook and Jeff Huber back Mammoth Biosciences

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing